Medical articles today

/* 728x15, */

Protalix Announces Presentation Of Phase III Taliglucerase Alfa Data At WORLD Lysosomal Disease Network

Protalix Biotherapeutics, Inc. (NYSE- Amex: PLX) announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida. Hanna Rosenbaum, M.D., Director of Hematology Day Care Unit, RAMBAM Medical Center, Haifa, Israel and study investigator, will give the oral presentation, titled: "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa, " on Thursday, February 11, 2010 at 10:15 AM ET.

CREON R pancrelipase Delayed-Release Capsules Significantly Improves Fat Absorption In Children With Cystic Fibrosis

Solvay Pharmaceuticals, Inc. announced that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food. In this clinical study, children aged 7-11 years with EPI due to CF experienced an improved coefficient of fat absorption (CFA) during treatment with CREON®

/* 468x60, */

PROLOR Biotech Reports Positive Top-Line Results From Phase I Study Of Its Longer-Acting Version Of Human Growth Hormone

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) reported positive top-line results from a Phase I study of its longer-acting version of human growth hormone (hGH). The study was designed to measure the potential durability (half-life), overall drug exposure (AUC) and biological efficacy, as well as the safety and tolerability of PROLOR's longer-acting CTP-modified human growth hormone (hGH-CTP). The Phase I study enrolled 24 healthy adults who were randomized to receive one of three doses of hGH-CTP (4mg, 7mg, or 21mg) or placebo. The study results showed that safety and tolerability endpoints were met at all doses in all participants.

JDRF-Funded Research Advances Potential For Regeneration As A Possible Cure For Type 1 Diabetes

A hormone responsible for the body's stress response is also linked to the growth of insulin-producing cells in the pancreas, according to JDRF- funded researchers at the Salk Institute for Biological Studies in California. The findings are the latest advances to underscore the potential for regeneration as a key component of a possible cure for type 1 diabetes. The research, which was published in the Proceedings of the National Academy of Sciences, was led by Wylie Vale, Ph.D., Professor and Head of the Clayton Laboratories for Peptide Biology and Mark O. Huising, Ph.D., a postdoctoral fellow at the Clayton Foundation Laboratories. The Juvenile Diabetes Research Foundation was a funder of the study.

Cedars-Sinai Researchers: Fat Behaves Differently In Patients With Polycistic Ovary Syndrome

Fat tissue in women with Polycystic Ovary Syndrome produces an inadequate amount of the hormone that regulates how fats and glucose are processed, promoting increased insulin resistance and inflammation, glucose intolerance, and greater risk of diabetes and heart disease, according to a study conducted at the Center for Androgen-Related Research and Discovery at Cedars-Sinai Medical Center. Polycystic Ovary Syndrome, or PCOS, is the most common hormonal disorder of women of childbearing age, affecting approximately 10 percent of women. It is the most common cause of infertility, and an important risk factor for early diabetes in women.

/* 468x60, */

The Endocrine Society Supports The American Diabetes Association's

The Endocrine Society released a statement supporting the American Diabetes Association's (ADA) new clinical practice recommendations adding the use of the A1C blood test to the traditional tests that use blood sugar measurements in the diagnosis of diabetes and pre-diabetes. The A1C measures the percentage of hemoglobin (the main component of red blood cells) in the blood that is glycated/has glucose attached to it. The A1C is currently the main blood test used in the management of diabetes because it reflects the average blood sugar levels for the previous two to three months. Now, the A1C can also be used as a diagnostic tool. "We commend the ADA for establishing this new criterion for clinicians to use in diagnosis, " said Robert A.

/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy